U.S., March 11 -- ClinicalTrials.gov registry received information related to the study (NCT07461220) titled 'Safety and Tolerability of IRL757 in Participants With Parkinson's Disease and Apathy' on Feb. 17.
Brief Summary: This clinical trial's goal is to evaluate if the IRL757 is safe and has a good tolerability in participants with Parkinson's disease and experiencing apathy (a lack of interest or motivation). In addition, the trial is aiming to learn if IRL757 has effects on the symptoms of Parkinson's disease. Researchers will compare the effects of IRL757 to a placebo (a look-alike substance that contains no drug).
Participants who fit the study criteria will be treated with the study drug (either the active drug IRL757 or placebo) ...